55044-06-9

Basic information

• Product Name: 2-Phenyloxazoline-4-carboxylic acid methyl ester
• Synonyms: 2-Phenyloxazoline-4-carboxylic acid methyl ester
• CAS NO: 55044-06-9
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.20994
• Mol File: 55044-06-9.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Ether, Ethyl Acetate, Methanol
• CAS DataBase Reference: 2-Phenyloxazoline-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyloxazoline-4-carboxylic acid methyl ester(55044-06-9)
• EPA Substance Registry System: 2-Phenyloxazoline-4-carboxylic acid methyl ester(55044-06-9)

Safety Data

• Hazardous Substances Data: 55044-06-9(Hazardous Substances Data)

Usage

Description

2-Phenyloxazoline-4-carboxylic acid methyl ester is an organic compound that serves as a crucial intermediate in the synthesis of pharmaceuticals. It is characterized by its oxazoline and carboxylic acid functional groups, which contribute to its reactivity and potential applications in the chemical and pharmaceutical industries.

Uses

Used in Pharmaceutical Industry:
2-Phenyloxazoline-4-carboxylic acid methyl ester is used as an intermediate for the synthesis of (S)-Valiolamine Voglibose, which is the main S-enantiomeric intermediate of Voglibose (V750000). Voglibose is an α-glucosidase inhibitor that helps in managing postprandial hyperglycemia and hyperinsulinemia by delaying the digestion and absorption of carbohydrates.

Upstream product

• 50-00-0 formaldehyd 
• 2104-89-4 Ser-OMe 
• 5873-90-5 methyl benzimidate hydrochloride 
• 2788-84-3 (S)-serine methyl ester 
• 5333-86-8 ethyl benzimidate hydrochloride 
• 59171-72-1 2-phenyl-oxazole-4-carboxylic acid methyl ester 
• 1137241-59-8 N-benzoyl-O-tritylserine methyl ester 
• 5680-80-8 methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride 
• 825-60-5 benzimidic acid ethyl ester 
• 20989-42-8 N-benzoylserine methyl ester 
• 5619-04-5 methyl 2-amino-3-hydroxypropanoate hydrochloride 
• 100-47-0 benzonitrile 
• 100-52-7 benzaldehyde 
• 932-90-1 Benzaldoxime 

Downstream Products

• 852945-55-2 ((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-(2-phenyl-4,5-dihydro-oxazol-4-yl)-methanone 
• 25755-94-6 methyl 2,5-diphenyloxazole-4-carboxylate 
• 1370731-50-2 C₂₂H₁₆N₂O₆ 
• 1370731-61-5 methyl 2-phenyl-5-(4-methylphenyl)oxazole-4-carboxylate 
• 1370731-62-6 methyl 2-phenyl-5-(3-methylphenyl)oxazole-4-carboxylate 
• 1370731-67-1 methyl 2-phenyl-5-(3,4-dichlorophenyl)oxazole-4-carboxylate 
• 1370731-68-2 methyl 2-phenyl-5-(2,3-dichlorophenyl)oxazole-4-carboxylate 
• 1370731-73-9 methyl 2-phenyl-5-(2,5-dimethylphenyl)oxazole-4-carboxylate 
• 1370731-75-1 methyl 2-phenyl-5-(3-nitrophenyl)oxazole-4-carboxylate 
• 1370731-78-4 C₁₇H₈⁽²⁾H₅NO₃ 
• 92-71-7 2,5-diphenyloxazole 
• 2549-35-1 2,5-diphenyl-4-hydroxymethyloxazole 
• 1613449-98-1 tert-butyl 2-(benzylamino)-2-(hydroxymethyl)butanoate 
• 1613450-04-6 tert-butyl 2-(benzylamino)-2-(hydroxymethyl)pentanoate 

Relevant articles and documents

I2-Catalyzed C-O Bond Formation and Dehydrogenation: Facile Synthesis of Oxazolines and Oxazoles Controlled by Bases

A general method for the synthesis of oxazolines and oxazoles was developed through I2-catalyzed C-O bond formation and dehydrogenation with the same oxidant, TBHP. By simply tuning reaction bases, either oxazolines or oxazoles were selectively

Pd(ii)-catalyzed direct C5-arylation of azole-4-carboxylates through double C-H bond cleavage

The first palladium-catalyzed direct C5-arylation of azole-4-carboxylates with simple unactivated arenes through double C-H bond cleavage is realized. This protocol provided a straightforward access to diverse 5-arylsubstituted azole-4-carboxylic derivatives with good functional group tolerance. The Royal Society of Chemistry 2012.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.